ATLANTA, GEORGIA / ACCESS Newswire / October 7, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company...
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSIONThe Summit theme "unlocking the $1 Trillion Wealth transfer...
Findings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A...
-- Integrating a computational workflow that leverages multi-omics data with a proprietary, humanized in vivo screening platform, T-knife identified highly...
MAIA’s Board of Directors authorizes holdings of up to 90% of the Company’s liquid assets in cryptocurrencies (BTC), Ethereum (ETH),...
MELBOURNE, Australia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company...
FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (“Cellectar” or the “company”), a late-stage biotechnology...
NORCROSS, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3...
New Predictive Platform Will Use Digital Technology and AI to Assist Clinician Decision-Making BRONX, N.Y., Oct. 6, 2025 /PRNewswire/ -- Serious...
SPOKANE, Wash., Oct. 6, 2025 /PRNewswire/ -- Gestalt is proud to announce the release of PathFlow Version 6, the latest evolution...
Michael Yeh promoted to Chief Medical Officer and Ian Vawter joins as Chief Financial Officer WALTHAM, Mass., Oct. 6, 2025...
Goal of POSEIDON is to enable accurate, low-cost, accessible cancer screening for all Americans Program to deliver first-in-class synthetic-sensor based...
Goal of POSEIDON is to enable accurate, low-cost, accessible cancer screening for all Americans Program to deliver first-in-class synthetic-sensor based...
SAN FRANCISCO, CALIFORNIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology...
October 6, 2025 Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference...
MaxCyte’s Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio’s engineered T cell therapiesROCKVILLE, Md., Oct. 06,...
SANTA ANA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage...
- Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with...
Exploring Strategic Partnerships to Expand Platform Beyond Reproductive HealthSAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:...
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to...